# Beta Bionics share price today (Beta Bionics, Inc., BBNX)

> Beta Bionics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BBNX · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/bbnx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $15.10 (−44.5% in a year)
- Revenue (Jun 2026): $32.0 M (+37.8% on a year ago)
- Profit (Jun 2026): −$23.4 M
- Operating margin: −79.9% (+5.6 points on a year ago)
- ROE: −26%, FY25
- ROIC: −16.3%

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Beta Bionics share price today? Beta Bionics, Inc.'s share price was $15.10 at the close on 3 November 2026. It has been stalling near its high for 13 weeks. That is 2.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. In the last 52 weeks it traded between $9 and $32, and at that close it sat 27% of the way up from that low. Over the last 1 year the share price moved −37% while the S&P 500 moved +25%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Beta Bionics pay? Beta Bionics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Beta Bionics on? Beta Bionics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Beta Bionics profitable? Beta Bionics, Inc. posted a net loss of $23.4 M in the Jun 2026 quarter. The full FY25 year was a loss of $73.2 M. That loss is 73.1% of the quarter's revenue. The same quarter a year earlier lost $16.9 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Beta Bionics make, and is it growing? Beta Bionics, Inc. reported $32.0 M of revenue in the Jun 2026 quarter, +37.8% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 3 years it has grown 724.3% a year on average. The last full year, FY25, came in at $100 M. The last four reported quarters add to $119 M. FY25 revenue was $100 M, +53.9% on the year before. Recent pace: the last four quarters grew +53.7% on average, against 724.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +52.5%, against +73.8% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Beta Bionics keep? Beta Bionics, Inc.'s operating margin was −79.9% in the Jun 2026 quarter, 5.6 percentage points higher than the same quarter a year ago. Across 4 years it has been between −36,169.8% and −69.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +5.6 percentage points on the year while gross margin changed +5.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Beta Bionics' profit turning into cash? Beta Bionics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $50.9 M of cash, against −$73.2 M of profit. After $5.3 M of spending on assets, free cash was −$56.2 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Beta Bionics' cash go? Beta Bionics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $9.1 M on assets over the last 3 years. Averaged over those years that is 3.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $9.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Beta Bionics' P/E ratio, and how does it compare with its own history? Beta Bionics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Beta Bionics, Inc. at 8.2× its FY25 revenue of $100 M. The P/E comes back here once profit turns positive. ## Is the Beta Bionics business getting better or worse? Beta Bionics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Beta Bionics earn on its capital? Beta Bionics, Inc. earned a ROE of −26% in FY25. That is up from a low of −498% in FY22. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −73.0% net margin and 0.30× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −73.0% net margin × 0.30× asset turnover × 1.14× leverage (assets divided by equity) ≈ −25.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Beta Bionics have too much debt? Beta Bionics, Inc. has total debt of $6.5 M against shareholder equity of $256 M as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.32 in FY22 to 0.03 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Beta Bionics shareholding pattern? 16.4% of Beta Bionics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Beta Bionics from balance-sheet trouble? For Beta Bionics, Inc., the Z-score is 10.25. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 10.25 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Beta Bionics rank in its industry? There is no score against its industry: Beta Bionics, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Beta Bionics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Beta Bionics in size? Beta Bionics is the 45th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: QuidelOrtho Corporation, Bioventus Inc. and AdaptHealth Corp. Just below it: OrthoPediatrics Corp., InMode and Varex Imaging Corporation. ### Medical Devices companies close in size

1. [QuidelOrtho Corporation](https://www.sectoralpha.in/us/stocks/qdel) $966 million
2. [Bioventus Inc.](https://www.sectoralpha.in/us/stocks/bvs) $920 million
3. [AdaptHealth Corp.](https://www.sectoralpha.in/us/stocks/ahco) $838 million
4. Beta Bionics, Inc. $821 million
5. [OrthoPediatrics Corp.](https://www.sectoralpha.in/us/stocks/kids) $820 million
6. [InMode Ltd.](https://www.sectoralpha.in/us/stocks/inmd) $809 million
7. [Varex Imaging Corporation](https://www.sectoralpha.in/us/stocks/vrex) $781 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Talkspace, Inc.](https://www.sectoralpha.in/us/stocks/talk) $871 million · Health Information Services
2. [Prospect Capital Corporation](https://www.sectoralpha.in/us/stocks/psec) $865 million · Asset Management
3. Beta Bionics, Inc. $864 million
4. [JBG SMITH Properties](https://www.sectoralpha.in/us/stocks/jbgs) $864 million · REIT - Diversified
5. [GMR Solutions Inc.](https://www.sectoralpha.in/us/stocks/gmrs) $863 million · Medical Care Facilities

## What else do people ask about Beta Bionics? ### What were Beta Bionics's latest quarterly results? Beta Bionics, Inc. reported revenue of $32.0 M and a net loss of $23.4 M for the Jun 2026 quarter. Earnings per share were −$0.53. The operating margin was −79.9%, 5.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Beta Bionics's market cap? Beta Bionics, Inc.'s market capitalisation is $821 M at a stock price of $15.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Beta Bionics performing? Beta Bionics, Inc.'s share price has been stalling near its high for 13 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Beta Bionics's stock price go up? This page does not forecast Beta Bionics, Inc.'s stock price. What it shows instead: the stock price is $15.10, and it has been stalling near its high for 13 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Beta Bionics have too much debt? No, Beta Bionics, Inc. has little debt: its debt is 0.02× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Beta Bionics in its business cycle? Beta Bionics, Inc.'s FY25 operating margin was −71.5%, against a 4-year range of −36,169.8% to −69.5%: the middle of its own range, neither a peak nor a low. The latest quarter was −79.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Beta Bionics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Beta Bionics a stock worth studying right now? What the numbers show: Beta Bionics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.